Unique ID issued by UMIN | UMIN000016128 |
---|---|
Receipt number | R000018672 |
Scientific Title | Detection of recurrence after radiation therapy using C-11 methionine PET |
Date of disclosure of the study information | 2015/01/08 |
Last modified on | 2019/05/30 15:41:54 |
Detection of recurrence after radiation therapy using C-11 methionine PET
Detection of recurrence after radiation therapy using C-11 methionine PET
Detection of recurrence after radiation therapy using C-11 methionine PET
Detection of recurrence after radiation therapy using C-11 methionine PET
Japan |
Primary or secoundary brain tumor, Tumor of the neighboring organ
Neurosurgery |
Malignancy
NO
We evaluate the usefulness of C-11 methionine comparing with F-18 FDG. C-11 methionine will be prepared using a methionine synthesizer (C-MET100).
Safety,Efficacy
Superiority of the sensitivity of C-11 methionine PETover that of F-18 FDG
"Efficacy:
(1)
Agreement between the histopathology result and C-11 methionine PET result and F-18 FDG
(2)
Positive-predictive value (PPV) of C-11 methionine PET
(3)
The number of cases that treatment strategy was changed from medical treatment to surgical or radiotherapy.
(4)
PET imaging agreement rate between readers of third party interpretation Committee
Safety: Adverse event
"
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Device,equipment |
PET
Not applicable |
Not applicable |
Male and Female
"(1)
The patients with suspected recurrence of tumor more than a half year after radiation theray
(2)
The patients that enough diagnosis information is not obtained by the common imaging (CT, MRI)
(3)
The patients or the patients that a written agreement is obtained about participation of this study by legal representative
"
"(1)
The patients with a history of hypersensitivity for C-11 methionine or F-18 FDG.
(2)
A pregnant woman, nursing mother and the women who may be pregnant
(3)
The patients who participate in other trials
(4)
The patients who receive C-11 methioine PET within 90 days
(5)
The patients whom it is assumed overall status to have difficulty in application of the surgical treatment
(6)
The patients whom brain metastasis appeared outside of radiation fields
(7)
The patients that a primary tumor and other metastases caused exacerbation for a metastatic brain tumor remarkably
(8)
The patients whom it was multiple, and metastasis appeared for a primary cerebral tumor any place other than fields
(9)
When it is multiple, and a lesion with suspected recurrence of tumor develops independently than three places outside in fields or fields
(10)
In addition, the patients whom a study person in charge judged to be inadequate as subjects
"
99
1st name | |
Middle name | |
Last name | Tohru Shiga |
Hokkaido University Hospital
Depertment of Nuclear Medicine
N15W7, Kita-ku, Sapporo, Hokkaido, Japan, 0608638
011-706-5152
tshiga@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Coordination Secretariat |
Hokkaido University Graduate School of Medicine
Depertment of Nuclear Medicine
N15W7, Kita-ku, Sapporo, Hokkaido, Japan, 0608638
011-706-5152
tshiga@med.hokudai.ac.jp
Hokkaido University Hospital
Japan Agency for Medical Research and Development
Japanese Governmental office
1.Osaka University Hospital
2.Fukushima Medical University Hospital
NO
大阪大学医学部附属病院(大坂府)
福島県立医科大学附属病院(福島県)
2015 | Year | 01 | Month | 08 | Day |
Unpublished
Terminated
2014 | Year | 12 | Month | 25 | Day |
2019 | Year | 03 | Month | 07 | Day |
2015 | Year | 01 | Month | 12 | Day |
2019 | Year | 03 | Month | 31 | Day |
2015 | Year | 01 | Month | 06 | Day |
2019 | Year | 05 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018672